Askal Ayalew Ali

7PUBLICATIONS
10CO-AUTHORS
Economic models and forecastingSocio-economic developmentEconomics, business and management curriculum and pedagogyMajor global burdens of diseaseCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 29, 2026
Estimating the Real Option Value of Osimertinib Compared to Standard EGFR-TKI in the Treatment of Advanced NSCLC in the United States.

|May 17, 2024
Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework.

Askal Ayalew Ali, Amit Kulkarni, Sandipan Bhattacharjee

|Nov 24, 2023
The State of Pharmacoeconomics Education in the Doctor of Pharmacy Curriculum amid the Changing Face of Pharmacy Practice.

Georges Adunlin, Jordan Skiera, Chandler S Cupp

|May 25, 2022
Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA.

Tadesse M Abegaz, Vakaramoko Diaby, Fatimah Sherbeny

|Feb 22, 2022
Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer.

Askal Ayalew Ali, Rima Tawk, Hong Xiao

|Nov 20, 2020
Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews.

Vakaramoko Diaby, Reem D Almutairi, Aram Babcock

Pageof 2

Frequent Collaborators

2 joint publications

Vakaramoko Diaby

2 joint publications

Richard K Moussa

1 joint publications

Reem D Almutairi

1 joint publications

Rima Tawk